What are the challenges of blinding in comparative effectiveness research?

A decentralized, Phase 2, randomized, double-blind study of Nirmatrelvir/Ritonavir compared with placebo/Ritonavir for long COVID. A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod (RPC1063) ... Upon receipt of the test material, researchers will record the date of receipt on their copy of DEA Form 222, or attach the documentation to their retained Copy ... Prospective Double-blind-study of Supplementary Antibiotic-therapy for Duodenal-ulcer Associated with Campylobacter Pyloridis Infection. American Journal of ... May 10, 2021 ... We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy ... Rituximab depletes B cells and may reduce the production of autoantibodies against PLA2R or THSD7A. Therefore, the measurement of autoantibodies in participants ... May 15, 2020 ... Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. The purpose of this research trial is to investigate the effects of LY3437943 (drug) compared with placebo on renal function, in participants who are ... Randomized double blind placebo control (RDBPC) studies are considered the “gold standard” of epidemiologic studies. In a blind or blinded experiment, information which may influence the participants of the experiment is withheld until after the experiment is complete.